UNSPSC 51192007: Amflutizole

This classification denotes a xanthine oxidase inhibitor with the molecular formula C11H7F3N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83N680M457, chemically known as 5-isothiazolecarboxylic acid, 4-amino-3-(3-(trifluoromethyl)phenyl)- but generally known as amflutizole, which bears US NIH Compound Identifier 54833. European Medicines Agency schedules Amflutizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05420MIG.

UNSPSC 51192007 Amflutizole, a Commodity code, shows minimal alignment with recent state and local procurement activity under this designation. The three most recent opportunities tagged to this code involve athletic training services for public safety employees (City of Tucson), general medical aid supplies for a fire department (City of Tampa), and a market-research request for information on direct-to-manufacturer pharmacy programs (Texas Health and Human Services Commission). None of these solicitations involve amflutizole procurement or pharmaceutical manufacturing; the code assignment appears to be a tagging error or system miscategorization rather than a reflection of actual buying activity under this specific pharmaceutical commodity.

The geographic spread spans Arizona, Florida, and Texas across city and state agencies, but the mismatch between the code's pharmaceutical scope and the nature of the opportunities limits decision relevance. The City of Tucson issued an RFP due June 9, 2026 for athletic training services with ongoing contract renewal options, the City of Tampa issued an ITB due April 9, 2025 (already passed) for first-aid and medical supplies under a $100,000 budget with set-aside provisions for small local business enterprises and underutilized women and minority-owned businesses, and the Texas Health and Human Services Commission issued an RFI closing April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs. The code shows no recent relevant opportunities for pharmaceutical suppliers; firms pursuing amflutizole or similar pharmaceutical commodities should verify category coding with issuing bodies or search under pharmaceutical supply family codes instead.